IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by Oppenheimer & Co. Inc.

Oppenheimer & Co. Inc. lowered its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 8.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 836 shares of the company’s stock after selling 80 shares during the period. Oppenheimer & Co. Inc.’s holdings in IDEXX Laboratories were worth $346,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of IDXX. Insight Wealth Strategies LLC lifted its stake in shares of IDEXX Laboratories by 230.5% in the 4th quarter. Insight Wealth Strategies LLC now owns 10,096 shares of the company’s stock worth $4,174,000 after acquiring an additional 7,041 shares during the period. Larson Financial Group LLC lifted its stake in shares of IDEXX Laboratories by 17,238.5% in the 3rd quarter. Larson Financial Group LLC now owns 2,254 shares of the company’s stock worth $1,139,000 after acquiring an additional 2,241 shares during the period. Quest Partners LLC lifted its stake in shares of IDEXX Laboratories by 4,059.4% in the 3rd quarter. Quest Partners LLC now owns 2,870 shares of the company’s stock worth $1,450,000 after acquiring an additional 2,801 shares during the period. Crystal Rock Capital Management lifted its stake in shares of IDEXX Laboratories by 90.0% in the 3rd quarter. Crystal Rock Capital Management now owns 9,005 shares of the company’s stock worth $4,550,000 after acquiring an additional 4,265 shares during the period. Finally, Victory Capital Management Inc. lifted its stake in shares of IDEXX Laboratories by 3.4% in the 3rd quarter. Victory Capital Management Inc. now owns 142,628 shares of the company’s stock worth $72,059,000 after acquiring an additional 4,696 shares during the period. Institutional investors and hedge funds own 87.84% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. Leerink Partners assumed coverage on shares of IDEXX Laboratories in a research note on Monday, December 2nd. They issued an “outperform” rating and a $500.00 target price for the company. StockNews.com downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Friday. Bank of America increased their price target on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a report on Tuesday, February 4th. Piper Sandler increased their price target on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a report on Monday, February 10th. Finally, Leerink Partnrs upgraded shares of IDEXX Laboratories to a “strong-buy” rating in a report on Monday, December 2nd. Four equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $533.75.

Insider Buying and Selling at IDEXX Laboratories

In other news, EVP George Fennell sold 9,986 shares of IDEXX Laboratories stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the sale, the executive vice president now directly owns 8,176 shares in the company, valued at $3,781,645.28. The trade was a 54.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the sale, the director now owns 3,061 shares of the company’s stock, valued at approximately $1,426,242.34. This trade represents a 49.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.11% of the stock is currently owned by insiders.

IDEXX Laboratories Stock Performance

NASDAQ:IDXX opened at $430.12 on Friday. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. The firm has a 50-day moving average price of $437.37 and a two-hundred day moving average price of $449.72. IDEXX Laboratories, Inc. has a twelve month low of $398.50 and a twelve month high of $574.94. The company has a market capitalization of $34.98 billion, a P/E ratio of 40.31, a price-to-earnings-growth ratio of 3.41 and a beta of 1.39.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.